Oncolytic virus replication system for external control 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
JP2007500012 A 2007-01-11 [JP2007500012] / 2007-01-11
申请号/申请日
2006JP-0532296 / 2004-02-24
发明人
;
申请人
CELL GENESYS;
主分类号
IPC分类号
A01N-063/00A01N-065/00A61K-031/7088A61K-035/76A61K-048/00A61P-035/00C12NC12N-001/00C12N-001/15C12N-001/19C12N-001/21C12N-005/10C12N-007/00C12N-015/09C12N-015/34C12N-015/67C12N-015/80C12N-015/86C12N-015/861
摘要
(JP2007500012) Compositions, methods and a system for external regulation of oncolytic virus replication are provided.  The oncolytic virus contains a cell type-specific transcriptional regulatory element (CT-TRE) and an inducible transactivator regulated transcriptional regulatory element.  The virus preferentially replicates in cells that allow a CT-TRE to function.  In addition, the concentration of an inducing agent or condition is used to regulate a transactivator regulated transcriptional regulatory element, thereby providing at least two levels of control of oncolytic viral replication.  (From WO2005007832 A3)
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2003US-60450232 2003-02-24 2004WO-US05518 2004-02-24
主权利要求
(JP2007500012) 1. Of the following: cell type-specific transcriptional response element (CT-TRE) under the transcriptional control of an inducible transcriptional transactivator coding sequence; transcriptional transactivator and the transcriptional response element regulated by a gene under the control of the adenovirus; comprising a replication competent adenovirus, or a vector, wherein, the exogenous transcriptional transactivator responsive functional to the inducer, adenovirus, the vector.  2. Wherein said adenoviral gene essential for replication of the adenovirus gene, the adenovirus according to claim 1, vector.  3. Wherein the adenovirus gene essential for replication is an early gene, the adenovirus according to claim 2, vector.  4. Wherein the adenovirus gene is E1A, the adenovirus according to claim 3, vector.  5. Wherein the adenovirus gene is E1B, the adenovirus according to claim 3, vector.  6. Wherein said adenovirus gene essential for replication of the adenovirus and the E4 of the gene, wherein the adenovirus 2, the vector.  7. Wherein the adenovirus is an adenovirus gene essential for replication is a late gene, the adenovirus according to claim 2, vector.  8. Wherein said transcriptional transactivator is inhibited by inducing agent, according to claim 1 adenovirus, vector.  9. Wherein said transcriptional transactivator is activated by an inducing agent, according to claim 1 adenovirus.  10. Claim inducers, tetracycline, doxycycline and its analogs, FKBP homodimers, ecdysone, rapamycin and its analogs selected from the group consisting of, according to claim 1 adenovirus.  11. Of the following: cell type-specific transcriptional response element (CT-TRE) under the transcriptional control of an inducible transcriptional transactivator coding sequence; above and regulated by a transcriptional transactivator under the control of a transcriptional response element adenoviral genes, and the first and second 2 under the control of a transcriptional response element and the second 2 gene; comprising a replication competent adenovirus, or a vector, wherein, where the transcriptional transactivator is activated by an exogenous inducer adenovirus, vector.  12. Wherein said first adenovirus gene is 2 gene, the adenovirus according to claim 11, vector.  13. Wherein the adenovirus gene is a gene essential for replication of adenovirus, adenovirus according to claim 12, vector.  14. Wherein the adenovirus is an adenovirus gene essential for replication is an early gene, the adenovirus according to claim 13, vector.  15. Wherein the adenovirus gene is E1A, the adenovirus according to claim 14, vector.  16. Wherein the adenovirus gene is E1B, the adenovirus according to claim 14, vector.  17. 2 And 1 wherein said first adenovirus gene essential for replication, adenovirus according to claim 12, vector.  18. Wherein the first and second adenovirus gene is 1 gene 2, according to claim 17 adenovirus, vector.  19. E1A And 1 wherein the first gene, and, in the first 2 E1B gene, the adenovirus according to claim 18, vector.  20. 2 Or 1 wherein the first IRES is regulated by the expression of a gene, the adenovirus according to claim 17, vector.  21. Wherein the first gene is introduced into the 2 gene, the adenovirus according to claim 11, vector.  22. Wherein the cytotoxic gene is a transgene, the adenovirus according to claim 21, vector.  23. Adenovirus according to claim 1, isolated host cell comprising the vector.  24. Adenovirus according to claim 1, vector, and a pharmaceutically acceptable composition comprising an excipient.  25. Of the following: cell type-specific transcriptional response element (CT-TRE) under the transcriptional control of an inducible transcriptional transactivator coding sequence; transcriptional transactivator and the transcriptional response element regulated by a gene under the control of the adenovirus; adenovirus comprising, method for propagation of the vector, in this case, the exogenous transcriptional transactivator is activated by an inducing agent, and the ability to replicate, the following steps: the adenovirus, the vector, the cell-specific TRE to function is allowed to be introduced into a cell; administered inducer described above and, in this case, the adenovirus, is propagated vector; comprising adenovirus, a method for propagation of the vector.  26. Of the following: cell type-specific transcriptional response element (CT-TRE) under the transcriptional control of an inducible transcriptional transactivator coding sequence; above and regulated by a transcriptional transactivator is under the transcriptional control of a response element for transcription of the gene of the adenovirus; adenovirus comprising, in a method for the regulation of the vector, in this case, the exogenous transcriptional transactivator is inhibited by inducing agent, the ability to replicate and, in the following step: the adenovirus, vector the cell-specific TRE to function is allowed to be introduced into a cell, wherein, the adenovirus, propagated vector; administered inducer described above and, in this case, the inhibition of propagation of the adenovirus; method comprising.  27. Of the following: a cell-type specific transcriptional response element (CT-TRE) under the transcriptional control of an inducible transcriptional transactivator coding sequence; above and regulated by a transcriptional transactivator is under the control of transcriptional response element adenoviral gene; selective cell lysis of tumor cells containing target method, wherein, the exogenous inducer to a transcriptional transactivator is activated by, the following steps: the adenovirus, vector the cell-specific TRE to function is allowed to be introduced into a cell; induction when administering the substance, wherein the adenovirus, the propagation of the vector, and then to cause lysis of target cells in the prostate gland; method comprising.
法律状态
(JP2007500012) LEGAL DETAILS FOR JP2007500012  Actual or expected expiration date=2010-04-30    Legal state=DEAD    Status=REVOKED     Event publication date=2004-02-24  Event code=JP/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=JP JP2006532296  Application date=2004-02-24  Standardized application number=2006JP-0532296     Event publication date=2007-01-11  Event code=JP/A  Event indicator=Pos  Event type=Examination events  Published application  Publication country=JP  Publication number=JP2007500012  Publication stage Code=A  Publication date=2007-01-11  Standardized publication number=JP2007500012     Event publication date=2007-02-21  Event code=JP/A621  Event indicator=Pos  Event type=Examination events  Written request for application examination  Effective date of the event=2007-02-20  JAPANESE INTERMEDIATE CODE: A621     Event publication date=2009-11-30  Event code=JP/A131  Event indicator=Neg  Event type=Examination events  Notification of reasons for refusal  Effective date of the event=2009-11-27  JAPANESE INTERMEDIATE CODE: A131     Event publication date=2010-05-06  Event code=JP/A02  Event indicator=Neg  Event type=Event indicating Not In Force  Decision of refusal  Effective date of the event=2010-04-30  JAPANESE INTERMEDIATE CODE: A02
专利类型码
A
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部